Medicofarma Biotech

Medicofarma Biotech Debt

Debt of Medicofarma Biotech (MDB.WA) as of Oct 15, 2026.

Debt

0.00PLN

Last updated:

In 2025, Medicofarma Biotech's total debt was 0.00 PLN, a % change from the 0.00 PLN total debt recorded in the previous year.

The Medicofarma Biotech Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
210,000.00 PLN
Jan 1, 2019
420,000.00 PLN
Jan 1, 2020
390,000.00 PLN
Jan 1, 2021
0.00 PLN
Jan 1, 2022
0.00 PLN
Jan 1, 2023
0.00 PLN
Jan 1, 2024
0.00 PLN
Jan 1, 2025
0.00 PLN
The Medicofarma Biotech Debt history
YEARDebtYoY
0.00PLN—
0.00PLN—
0.00PLN—
0.00PLN—
0.00PLN-100.00%
390,000.00PLN-7.14%
420,000.00PLN+100.00%
210,000.00PLN—
0.00PLN—
0.00PLN—
0.00PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Medicofarma Biotech Stock analysis

What does Medicofarma Biotech do? Medicofarma Biotech is one of the most popular companies on Eulerpool.

Debt Details

Understanding Medicofarma Biotech's Debt Structure

Medicofarma Biotech's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Medicofarma Biotech's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Medicofarma Biotech’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Medicofarma Biotech’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Medicofarma Biotech stock

On Eulerpool you can find the complete historical development of Debt Medicofarma Biotech since 2006 – with annual values, charts, and detailed analysis.

Debt's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Medicofarma Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Medicofarma Biotech

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Medicofarma Biotech